Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.40 |
| ▸ | RAB9A | P51151 | 11/20 | 0.40 |
| ▸ | MEN1 | O00255 | 11/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.38 |
| ▸ | RELA | Q04206 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356516 | 0.88 | GRM4 (0.35) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL3356647 | 0.88 | GRM4 (0.35) | NPC1RAB9AMEN1KMT2AGRM4 | |
| SCHEMBL3354402 | 0.84 | GRM4 (0.44) | NPC1RAB9AMEN1KMT2AKDR | |
| SCHEMBL3356660 | 0.81 | RAB9A (0.56) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL370608 | 0.78 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL3359649 | 0.78 | KDR (0.45) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL3360051 | 0.77 | RAB9A (0.41) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL3355817 | 0.77 | ALDH1A1 (0.41) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL3355680 | 0.68 | GRM4 (0.38) | NPC1RAB9AMEN1KMT2AKDR | |
| SCHEMBL3357491 | 0.67 | GRM4 (0.38) | NPC1RAB9AMEN1KMT2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-10 | — | — | US | claimed |
| US-8524718-B2 | Heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20120329811-A1 | Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | BOLEA CHRISTELLE (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM4, GRM2 | NPC1 2378/4885RAB9A 2813/4885MEN1 3884/4885 |
| US-20120329811-A1 | Heteroaromatic Derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | GRM3, GRM4, GRM1 | NPC1 2504/4885RAB9A 3067/4885MEN1 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.